Related Experiment Video
Updated: Aug 14, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion
Theodoros Foukakis1, Amy Y M Au, Göran Wallin
1Department of Molecular Medicine and Surgery, Karolinska University Hospital, CMM L8:01, SE-171 76 Stockholm, Sweden. theodoros.foukakis@ki.se
Context:
The Ras effector NORE1A (RASSF5A) is a putative tumor suppressor and is inactivated in several human cancers. NORE1A has not been studied in thyroid cancer.
Objective:
The objective of this study was to investigate whether NORE1A is involved in follicular thyroid cancer (FTC) development.
Design:
We analyzed NORE1A expression in 25 FTCs, eight follicular thyroid adenomas, and seven normal thyroid tissues by TaqMan quantitative RT-PCR. The results were evaluated in relation to RASSF1A expression, RAS mutations, and PAX8-PPARgamma fusions assessed in the same material. NORE1A promoter methylation was assessed by the combined bisulfite restriction endonuclease assay.
Results:
Although the NORE1A mRNA levels of the majority of the tumors were similar to those in the normal controls, the cases harboring a PAX8-PPARgamma translocation (n = 6) exhibited dramatically reduced NORE1A expression (P < 0.001). In contrast, RAS mutations (n = 5) and NORE1A down-regulation were mutually exclusive. A significant reduction in the expression of the NORE1A homolog and the bona fide tumor suppressor gene RASSF1A was observed, but with weak correlation to the respective NORE1A values. No NORE1A promoter methylation was detected in the 32 thyroid tumors analyzed.
Conclusions:
Our experiments demonstrate the suppression of NORE1A, a known Ras effector, in PAX8-PPARgamma carrying FTCs.
Insights
NORE1A, a tumor suppressor, is suppressed in follicular thyroid cancers with PAX8-PPARgamma translocations. This Ras effector
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The Ras effector NORE1A (RASSF5A) acts as a tumor suppressor and is inactivated in various human cancers.
- NORE1A's role in thyroid cancer has not been previously investigated.
Purpose of the Study:
- To determine if NORE1A is implicated in the development of follicular thyroid cancer (FTC).
Main Methods:
- Quantitative RT-PCR was used to analyze NORE1A expression in FTCs, adenomas, and normal thyroid tissues.
- Analysis included RASSF1A expression, RAS mutations, and PAX8-PPARgamma fusions.
- NORE1A promoter methylation was assessed using bisulfite restriction endonuclease assay.
Main Results:
- FTCs with PAX8-PPARgamma translocations showed significantly reduced NORE1A expression.
- RAS mutations and NORE1A down-regulation were found to be mutually exclusive.
- A reduction in RASSF1A expression was observed, but with limited correlation to NORE1A levels.
- No NORE1A promoter methylation was detected in any of the analyzed thyroid tumors.
Conclusions:
- NORE1A, a Ras effector, is suppressed in FTCs that harbor PAX8-PPARgamma translocations.
- These findings suggest a potential role for NORE1A in FTC pathogenesis, particularly in tumors with specific genetic alterations.
Related Concept Videos
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
The Ras Gene
Ras is a superfamily...
Abnormal Proliferation
Directionality of Nuclear Transport
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
